Imara Inc Stock, NASDAQ:IMRA
Imara, Inc. is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Boston, MA.